BLOCK HF trial
This article was originally published in The Gray Sheet
Executive Summary
Ability of Medtronic's InSync III cardiac resynchronization device to slow the progress of NYHA Class I, II and III heart failure with bi-ventricular pacing will be assessed in the 1,200-patient, 65-center trial. The first U.S. implant was announced Jan. 22. BLOCK HF is similar to Guidant's recently launched MADIT-CRT trial, which will evaluate the Contak Renewal 3 ICD's ability to retard HF progression (1"The Gray Sheet" Nov. 10, 2003, p. 42)...
You may also be interested in...
Guidant Plans CRT Trial Aimed At Slowing Heart Failure In Healthier Patients
Expansion of the approved indication for cardiac resynchronization therapy (CRT) to include early-stage heart failure (HF) patients will be pursued by Guidant via its planned MADIT-CRT trial, the firm says
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.